# US 2003/0216336 A1 · Suppression of nuclear factor-kappaB dependent processes using oligonucleotides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216336 A1
- Document ID: US20030216336A1
- Status: Published application
- Kind: A1
- Application number: 10/328,861
- Filed: 2002-12-24
- Published: 2003-11-20
- Earliest claimed: 1992-05-22
- Assignees: The Scripps Research Institute
- Inventors: Michael I. Nerenberg; Isao Kitajima
- Web page: https://patentgrep.com/patent/US20030216336A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/1132: {against retroviridae, e.g. HIV}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/315: Phosphorothioates
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Antisense oligonucleotides which hybridize with nuclear factor-κB(NF-κB) mRNA and methods of using these oligonucleotides.

## Claims

### Claim 1

An antisense oligonucleotide complementary to a region of a nuclear factor-κB(NF-κB) subunit mRNA comprising a nucleic acid sequence hybridizing to the mRNA.

### Claim 2 (depends on 1)

The antisense oligonucleotide of claim 1, which comprises a nucleic acid sequence complementary to the translation initiation nucleic acid sequence of the NF-κB subunit.

### Claim 3 (depends on 1)

The antisense oligonucleotide of claim 1, which is from about 8 to about 40 nucleic acid residues in length.

### Claim 4 (depends on 1)

The antisense oligonucleotide of claim 1, which is chemically modified.

### Claim 5 (depends on 4)

The antisense oligonucleotide of claim 4, which is chemically modified by substitution in a non-bridging oxygen atom of the antisense nucleic acid backbone with a moiety selected from the group consisting of methane phosphate, methyl phosphate, and phosphorothioate.

### Claim 6 (depends on 5)

The antisense oligonucleotide of claim 5, wherein the substitution is at a terminal region selected from the group consisting of the 3′ region and the 5′ region.

### Claim 7 (depends on 6)

The antisense oligonucleotide of claim 6, wherein the terminal region is the 3′ terminal region.

### Claim 8 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the NF-κB subunit, to which the antisense nucleic acid is against, is selected from the group consisting of p65 and p50.

### Claim 9 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the antisense nucleic acid is DNA.

### Claim 10 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the antisense nucleic acid is RNA.

### Claim 11 (depends on 1)

The antisense oligonucleotide of claim 1 capable of hybridizing to a DNA sequence selected from the group consisting of:
2 3′ TAG CAG ACG GTA CCA CTT CTA 5′; 3′ CTT GTC AAG CAG GTA CCG GC 5′; and 3′ TTT GTC TAG CAG GTA CCA GT 5′.

### Claim 12 (depends on 11)

The antisense oligonucleotide of claim 11, which is selected from the group consisting of:
3 5′ ATC GTC TGC CAT GGT GAA GAT 3′; 5′ GAA CAG TTC GTC CAT GGC CG 3′; 5′ AAA CAG ATC GTC CAT GGT CA 3′; and 5′ TC GTC TGC CAT GGT GAA GAT 3′.

### Claim 13

A recombinant DNA sequence which, upon translation, produces an antisense oligoribonucleotide against a NF-κB subunit mRNA, wherein the antisense oligoribonucleotide comprises a nucleic acid sequence hybridizing to the mRNA.

### Claim 14 (depends on 1)

A method of suppressing NF-κB dependent processes in an individual which comprises administering a therapeutically effective amount of the antisense oligonucleotide of claim 1.

### Claim 15 (depends on 0)

The method of claim 0.14, wherein the antisense oligonucleotide is complementary to the translation initiation nucleic acid sequence of the NF-κB subunit.

### Claim 16 (depends on 14)

The method of claim 14, wherein the antisense oligonucleotide is from about 8 to about 40 nucleic acid residues in length.

### Claim 17 (depends on 14)

The method of claim 14, wherein the antisense oligonucleotide is chemically modified.

### Claim 18 (depends on 17)

The method of claim 17, wherein the antisense oligonucleotide is chemically modified by substitution in a non-bridging oxygen atom of the antisense oligonucleotide backbone with a moiety selected from the group consisting of methane phosphate, methyl phosphate, and phosphorothioate.

### Claim 19 (depends on 18)

The method of claim 18, wherein the antisense oligonucleotide is substituted at a terminal region selected from the group consisting of the 3′ region and the 5′ region.

### Claim 20 (depends on 19)

The method of claim 19, wherein the antisense oligonucleotide terminal region is the 3′ terminal region.

### Claim 21 (depends on 14)

The method of claim 14, wherein the NF-κB subunit, to which the antisense oligonucleotide is against, is selected from the group consisting of p65 and p50.

### Claim 22 (depends on 14)

The method of claim 14, wherein the antisense oligonucleotide is DNA.

### Claim 23 (depends on 14)

The method of claim 14, wherein the antisense oligonucleotide is RNA.

### Claim 24 (depends on 14)

The method of claim 14, wherein the antisense oligonucleotide is capable of hybridizing to a DNA sequence selected from the group consisting of:
4 3′ TAG CAG ACG GTA CCA CTT CTA 5′; 3′ CTT GTC AAG CAG GTA CCG GC 5′; and 3′ TTT GTC TAG CAG GTA CCA GT 5′.

### Claim 25 (depends on 24)

The method of claim 24, wherein the antisense oligonucleotide is selected from the group consisting of:
5 5′ ATC GTC TGC CAT GGT GAA GAT 3′; 5′ GAA CAG TTC GTC CAT GGC CG 3′; 5′ AAA CAG ATC GTC CAT GGT CA 3′; and 5′ TC GTC TGC CAT GGT GAA GAT 3′.

### Claim 26 (depends on 14)

The method of claim 14, wherein the antisense oligonucleotide is administered in combination with a glutathione precursor.

### Claim 27 (depends on 26)

The method of claim 26, wherein the antisense oligonucleotide and glutathione precursor are administered substantially contemporaneously.

### Claim 28 (depends on 26)

The method of claim 26, wherein the glutathione precursor is an acylcysteine.

### Claim 29 (depends on 28)

The method of claim 28, wherein the acylcysteine is N-acetylcysteine.

### Claim 30 (depends on 1)

A pharmaceutical combination comprising the antisense oligonucleotide of claim 1, in combination with a glutathione precursor.

### Claim 31 (depends on 14)

The method of claim 14, wherein the NF-κB dependent process is septic shock.

### Claim 32 (depends on 14)

The method of claim 14, wherein the NF-κB dependent process is tissue specific.

### Claim 33 (depends on 32)

The method of claim 32, wherein the tissue is selected from the group consisting of kidney, liver, and spleen.

### Claim 34 (depends on 1)

A method of monitoring the effectiveness of suppressing NF-κB dependent processes in the tissue of an individual after administering a therapeutically effective amount of the antisense oligonucleotide of claim 1, comprising detecting the level of cytokine production in a tissue before and after the antisense therapy.

### Claim 35 (depends on 34)

The method of claim 34, wherein the cytokine is IL-6.
